Johnson & Johnson invested USD 2 billion in North Carolina as it plans to expand its U.S. manufacturing presence amid looming drug import duties proposed by President Donald Trump's administration. Prominent drugmakers, including Eli Lilly and AstraZeneca, have also planned to shell out billions of dollars to scale up their U.S. footprint.
Johnson & Johnson has reached a 10-year bond with Tokyo-based contract drug developer Fujifilm Diosynth for its more than 160,000-square-foot manufacturing facility in Holly Springs, North Carolina, which would create about 120 new opportunities.
This initiative will reinforce Johnson & Johnson’s leadership in delivering cutting-edge healthcare services and will enable the Company to manufacture the vast majority of their advanced medicines in the U.S. to meet the needs of U.S. patients.
The company would also introduce plans for additional manufacturing facilities in the U.S. and the expansion of current U.S. sites in the coming months.
The Company announced it will invest USD 55 billion in March to support U.S. manufacturing, research and development, and technology investments.
- Progress continues in the construction of the Wilson, North Carolina, facility, which will employ more than 500 people when fully operational and create approximately 5,000 construction jobs during the site development.
The company’s strength in healthcare innovation empowers to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal.
Executive Statement
According to Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson, Johnson & Johnson has more manufacturing facilities in the U.S. than in any other country, and they continue to strengthen our presence in U.S. With the recent signing of the One Big Beautiful Bill Act, they continue to expand their investment in the U.S. to lead the next era of healthcare innovation.
